

MASS SPECTROMETRY FOR CHARACTERIZING HUMAN INTERNAL CHEMICAL EXPOSURE: STRENGTHS AND CHALLENGES



Laboratoire d'Étude des Résidus et Contaminants dans les Aliments (LABERCA)

USC INRA 1329, Oniris, LUNAM Université
BP 50707, 44307 Nantes Cedex 3, France - www.laberca.org




Jean-Philippe ANTIGNAC

Philippe Marchand, Ronan Cariou,
Bruno Veyrand, Anaïs Venisseau,
German Cano-Sancho, Stéphane Ploteau,
Emmanuelle Bichon, Ingrid Guiffard,
Yann Guitton, Fabrice Monteau, Bruno Le Bizec



- Public laboratory (50 people)
 - Research (UMR 1329 Oniris-INRA)
 - Method development & innovation
 - Support to public authorities (NRL)
 - MS based analytical platform
 - Training and pedagogical engineering



Outline

- Introduction
- How measuring ?
- Where measuring ?
- When measuring ?
- What measuring ?
- Conclusion



Temporal increase of human exposure to environmental chemicals






Figure 5. Time trend of the sum concentrations of 8 PBDE congeners in pooled mother's milk samples from Swedish mothers living in the Stockholm region. Data from Norén and Meironyté (57).



Temporal increase of some human health outcomes


Reproduction & development

(↓ sperm quality & age of puberty)




Cancer



(↗ breast & prostate cancers incidence)

Metabolism & immune system
(obesity, metabolic syndrome, allergy...)

Need for human chemical exposure data



Now... how, where, and when measuring what ?



Parent compounds?
Direct metabolites?
Indirect biomarkers?

Dioxins Phytosanitary
PCBs PAHs Drugs
BFRs PFAS Bisphenols
Metals Phtalates ...

Outline

- Introduction


- How measuring ?

- Where measuring ?


- When measuring ?

- What measuring ?

- Conclusion



- Extremely low concentration levels



- Very complex biological matrices



- Need for unambiguous identification and precise/accurate quantification



How measuring ?

The mass spectrometric advantage



UPLC/APGC-MS/MS (x 2)



LC-HRMSⁿ (x 3)



UPLC/SFC-IM-HRMS (x 1)



GC-MS (x 3)



GC-MS/MS (x 2)



GC-HRMS (x 3)



HPLC-UV/DAD (x 2)



LC-MS/MS (x 2)








GC-C-IRMS (x 3)

How measuring ?

The mass spectrometric advantage

Dioxins/PCB/PBDE





How measuring ?

The mass spectrometric advantage



Dioxins/PCB/PBDE





Compound View
JEOL DioxK V4.02 2018/04/11 14:28:52 Page 1
DqData: 20180320-800-PCB-INV5 (), Injection= 18.204.10 (UNK)
Original: 20180320-800-PCB-INV5001.mfl, InjectionNo= 18, Sample= 18.204.10.dli, Date= 2018/3/21 2:10:55





Compound View
JEOL DioxK V4.02 2018/04/11 14:37:44 Page 1
DqData: 20180320-800-PCB-INV5 (), Injection= 17.1505.6 (UNK)
Original: 20180320-800-PCB-INV5001.mfl, InjectionNo= 13, Sample= 17.1505.6.dli, Date= 2018/3/20 22:13:59



Compound View
JEOL DioxK V4.02 2018/04/11 14:42:26 Page 1
DqData: 20170306-800-PBDE-PBB-INV5 (), Injection= 16.2062.146 (UNK)
Original: 20170306-800-PBDE-PBB-INV5-2016001.mfl, InjectionNo= 18, Sample= 16.2062.146, Date= 2017/3/6 23:6:2








Compound View
JEOL DioxK V4.02 2018/04/11 14:43:58 Page 1
DqData: 20170328-800-Deca-INV5 (), Injection= 16.2065.10 (UNK)
Original: 20170328-800-Deca-INV5-2016001.mfl, InjectionNo= 21, Sample= 16.2065.10, Date= 2017/3/28 14:37:07



How measuring ?

The mass spectrometric advantage


Organochlorine pesticides




How measuring ?

The mass spectrometric advantage


Organochlorine pesticides







Compound View
JEOL DioK V4.02 2018/04/11 14:51:06 Page 1
DqData: 20170502-700-POC (), Injection= 17.236.5 (UNK)
Original: 20170502-700-POC001.mfl, InjectionNo= 14, Sample= 17.236.5, Date= 2017/5/2 8:12:37



Compound View
JEOL DioK V4.02 2018/04/11 15:50:32 Page 1
DqData: 20170502-700-POC (), Injection= 17.236.6 (UNK)
Original: 20170502-700-POC001.mfl, InjectionNo= 15, Sample= 17.236.6, Date= 2017/5/2 8:48:20






Compound View
JEOL DioK V4.02 2018/04/11 15:51:31 Page 1
DqData: 20170502-700-POC (), Injection= 17.236.4 (UNK)
Original: 20170502-700-POC001.mfl, InjectionNo= 13, Sample= 17.236.4, Date= 2017/5/2 7:37:6





How measuring ?

The mass spectrometric advantage



Perfluorinated alkylated substances (PFAS)



Perfluorooctanesulfonic acid



Perfluorooctanoic Acid




Perfluorohexane sulfonate

Perfluorinated alkylated substances (PFAS)




17.274.2
20170617042



11: MRM of 4 Channels ES-
498.9 > 80 (PFOS)
1.49e6
Area

12C PFOS
Signal 1
0.25 ng/mL


20170617042



11: MRM of 4 Channels ES-
498.9 > 99 (PFOS)
6.10e5
Area

12C PFOS
Signal 2

20170617042



11: MRM of 4 Channels ES-
502.9 > 80 (MPFOS)
4.53e5
Area

13C PFOS

11: MRM of 4 Channels ES-
498.9 > 80 (PFOS)
1.49e6
Area

17.274.2
20170617042

100

%

0

Time

3.90

4.00

4.10

4.20

4.30

4.40

4.50

4.60

4.70

100

%

0

Time

3.40

3.50

3.60

3.70

3.80

3.90

4.00

4.10

4.20

4.30

4.40

4.50

4.60

4.70

4.80

4.90

5.00

5.10

5.20

5.30

5.40

5.50

5.60

5.70

5.80

5.90

6.00

6.10

6.20

6.30

6.40

6.50

6.60

6.70

6.80

6.90

7.00

7.10

7.20

7.30

7.40

7.50

7.60

7.70

7.80

7.90

8.00

8.10

8.20

8.30

8.40

8.50

8.60

8.70

8.80

8.90

9.00

9.10

9.20

9.30

9.40

9.50

9.60

9.70

9.80

9.90

10.00

100

%

0

Time

3.40

3.50

3.60

3.70

3.80

3.90

4.00

4.10

4.20

4.30

4.40

4.50

4.60

4.70

4.80

4.90

5.00

5.10

5.20

5.30

5.40

5.50

5.60

5.70

5.80

5.90

6.00

6.10

6.20

6.30

6.40

6.50

6.60

6.70

6.80

6.90

7.00

7.10

7.20

7.30

7.40

7.50

7.60

7.70

7.80

7.90

8.00

8.10

8.20

8.30

8.40

8.50

8.60

8.70

8.80

8.90

9.00

9.10

9.20

9.30

9.40

9.50

9.60

9.70

9.80

9.90

10.00

10.10

10.20

10.30

10.40

10.50

10.60

10.70

10.80

10.90

11.00

11.10

11.20

11.30

11.40

11.50

11.60

11.70

11.80

11.90

12.00

12.10

12.20

12.30

12.40

12.50

12.60

12.70

12.80

12.90

13.00

13.10

13.20

13.30

13.40

13.50

13.60

13.70

13.80

13.90

14.00

14.10

14.20

14.30

14.40

14.50

14.60

14.70

14.80

14.90

15.00

15.10

15.20

15.30

15.40

15.50

15.60

15.70

15.80

15.90

16.00

16.10

16.20

16.30

16.40

16.50

16.60

16.70

16.80

16.90

17.00

17.10

17.20

17.30

17.40

17.50

17.60

17.70

17.80

17.90

18.00

18.10

18.20

18.30

18.40

18.50

18.60

18.70

18.80

18.90

19.00

19.10

19.20

19.30

19.40

19.50

19.60

19.70

19.80

19.90

20.00

20.10

20.20

20.30

20.40

20.50

20.60

20.70

20.80

20.90

21.00

21.10

21.20

21.30

21.40

21.50

21.60

21.70

21.80

21.90








22.00

22.10

How measuring ?

The mass spectrometric advantage




Bisphenols



How measuring ?

The mass spectrometric advantage

Bisphenols




The external contamination for ubiquitous contaminants


Enzymatic hydrolysis



SPE HR-X



SPE MIP





N_2 evaporation



MSTFA derivatization





GC-MS/MS measurement



The sensitivity

- Very restricted samples amounts typically available for human studies
- Global decrease of environmental exposure for historical substances
- Exposure levels even lower for particular sub-populations (children)
- Low dose and mixture effect studies also push toward more sensitivity
- Low fat content of serum increase again the analytical challenge for POPs



Example of dioxins and PCBs

Evolution of the detection capabilities
and sample amounts for analysis

Non measurable	20 mL	10 mL	5 mL	1 mL
1990	2000	2010	2015	202x

→ Continuous methodological and technological developments still useful and necessary
(High selectivity of sample preparation + high sensitivity of MS measurement).

Outline

- Introduction
- How measuring ?
- Where measuring ?
- When measuring ?
- What measuring ?
- Conclusion



What rationale for considering a target biological matrix in environment-health studies?

- Representativeness / internal exposure level
- Relevance / considered health outcome
- Precise sampling localization and conditions
- Multicompartment investigations = multiple analytical challenges
- Cartography of chemical residues = practical and cost limitations



Hair



Adipose tissue



Blood



Milk



Urine



Meconium



Reservoir
compartments





Circulating
compartments

Excretion
compartments



Are different adipose tissue depots equivalent in terms of POPs concentration levels?

- POPs levels in superficial and deep AT appeared equivalent in steady-state individuals
- No necessarily the case for all chemicals and depends on individual's weight stability




Ploteau et al., Environ. Int. 97 (2016) 125-136.


Are adipose tissue and serum equivalent in terms of POPs information / health outcome?

- Good correlation serum/AT usually observed for POPs but not for all chemicals
 - Higher variability typically observed in serum (analytical + biological)
 - Stored/circulating ratio as new integrative marker
 - Still non definitive approach for relying exposure and health outcome

Cases (endometriosis) vs. Controls



Association between exposure and endometriosis (odd ratio)





Ploteau et al., Environ. Int. 108 (2017) 195-203.

Cano-Sancho et al., Chemosphere 2018 in press.

Are maternal and cord serum correlated in terms of POPs concentration levels?




- Good maternal/cord serum correlation observed for PFAS
- Cord vs. maternal ratio depends on the considered compound



Cariou et al, Environ. Int. 84 (2015) 71–81.

Are maternal and cord serum correlated / non persistent chemicals concentrations?

- Poor maternal/cord serum correlation observed for bisphenols



Antignac et al., manuscript in preparation.



Does breast milk a good option for assessing maternal and fetal exposure?

- Global significant correlation between levels in adipose tissue and breast milk for POPs
- Stronger association for lowest *versus* highest brominated PBDE congeners




PBDE#28 (tri-BDE)



PBDE#153 (Hexa-BDE)




PBDE#183 (Hepta-BDE)



Antignac et al., Environ Pollut. 157 (2009) 164-173.

Does breast milk a good option for assessing maternal and fetal exposure?

- Milk transfer rate depends on substance chemistry and other factors (BMI, weight gain/loss, diet...)



Outline

- Introduction


- How measuring ?

- Where measuring ?

- When measuring ?


- What measuring ?

- Conclusion




What rationale for getting a fix snapshot from a moving process?

Intra-individual temporal variability in terms of chemical exposure and related internal dose



Long term effects of early exposure
"Developmental Origins of Health and Disease (DOHaD)"



Chemicals hypothesized to be a factor of:


- Disease induction/apparition?
- Disease development/progression?
- Disease programming?

Determining the exposure levels:


- At the time of the disease diagnostic?
- At one earlier (critical) time windows?
- At birth?

Use a full life animal model

Investigating the POPs internal exposure levels and contamination profiles in dogs *versus* human



Concentration levels of dl-PCB (OMS-TEQ) determined in dog *versus* human according to the age of individuals.



Relative contribution of some PCB congeners to the total PCB internal exposure observed in dog *versus* human individuals.

Sévere et al, manuscript in preparation.

→ Pet dog model not fully satisfying as sentinel of human chemical exposure.

Model a full life exposure from one or several isolated measurements

Physiologically Based Pharmacokinetic Modeling of Persistent Organic Pollutants for Lifetime Exposure Assessment: A New Tool in Breast Cancer Epidemiologic Studies

Marc-André Verner,¹ Michel Charbonneau,^{2*} Lizbeth López-Carrillo,³ and Sami Haddad^{1*}

¹Département des sciences biologiques, Université du Québec à Montréal, Montréal, Québec, Canada; ²INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; ³Instituto Nacional de Salud Pública, Cuernavaca, Mexico




Figure 3. Toxicokinetic profiles for PCB-153, PCB-180, and HCB blood concentration for (A) normal body weight history and 10 ng/kg/day exposure to each of these chemicals for a woman who was not breast-fed in childhood (blue line) or breast-fed for 6 months (black line); (B) normal weight (gray line), weight loss (black line), or overweight (blue line) profiles and 10 ng/kg/day exposure to each of these chemicals for women who were breast-fed for 6 months in childhood; (C) normal body weight history and 10 ng/kg/day exposure to each of these chemicals for a woman who was breast-fed for 6 months in childhood and had a pregnancy at 30 years of age followed by no lactation (blue line) or a 12-month lactation period (black line); (D) normal body weight history and 10 ng/kg/day exposure to each of these chemicals for a woman who was breast-fed for 6 months in childhood and had a pregnancy followed by a 12-month lactation period at 20 years of age (blue line) or 35 years of age (black line); (E) normal body weight history and 10 ng/kg/day exposure to each of these chemicals for a woman who had a pregnancy at 35 years of age followed by a 6-month lactation period (blue line) or a 12-month lactation period (black line); (F) normal body weight history for a woman who was exposed to 10 ng/kg/day of each of the three chemicals and had no pregnancy (black line) or was breast-fed for 6 months in childhood, was exposed to 18.7 ng/kg/day PCB-153, 13.8 ng/kg/day PCB-180, 11.6 ng/kg/day HCB, and who had two pregnancies at 35 and 40 years of age followed by 12-month lactation periods (blue line).

→ Statistical / conceptual developments running but pieces of knowledge still missing.

Outline

- Introduction


- How measuring ?

- Where measuring ?

- When measuring ?

- What measuring ?

- Conclusion



What measuring?

The problematic


More and more chemicals in our environment to be considered for risk assessment



Scientific vs. practical and economical issues is the main constraining frame of environmental-health studies



Several options may be envisaged



- Limit the number of targeted POPs families?
 - Limit the number of targeted congeners among each POPs family?
 - Increase the methodological capabilities?
 - Develop new approaches based on integrative biomarkers?



What measuring?

More restricted contamination profiles?



DEER project – “Developmental Effects of Environment on Reproduction”, Coord. : Univ Turku, J Toppuri
Collab. Rigshospitalet, Copenhagen, DK (Katharina Main, Niels E Skakkebaeck)

Can the exposure levels determined for some POPs classes be predictive of the other classes?




Antignac et al. *Organohalogen compounds* 2012.
Wohlfahrt Veje et al. *EHP* 2014;147(4):391-399.
Antignac et al., *Environ Pollut.* 218 (2016) 728-738.

→ Global POPs contamination profiles can not be restricted to a limited number of families.



Can the exposure levels determined for particular POPs congeners be predictive of the others?



- No correlation relation between \neq PFAS compounds

Cariou et al, Environ. Int. 84 (2015) 71–81.

- Country dependent correlation between 2 PCDD congeners

Antignac et al., Environ Pollut. 218 (2016) 728-738.

→ Global POPs contamination profiles can not be restricted to a limited number of congeners.

What measuring?


Suspect screening

- Trend observed with the relative democratization of HRMS
- Wider coverage but lower quantitative performances
- Still depends on sample preparation
- Need for extended and QA/QC consolidated ref. library


Human samples



High Resolution Mass Spectrometry Profiling
(LC-HRMS, GC-HRMS, GCxGC-HRMS)




Peak annotation



Annotated profile



MS Reference Library




Accurate mass
Retention time
MS spectrum
MS/MS spectrum

- “Fishing” emerging substances & new markers discovery
- Still depends on sample preparation
- Need for advanced expertise for data processing & analysis
- Need for advanced expertise for structural elucidation

Human samples




Raw or annotated HRMS Profile
(LC-HRMS, GC-HRMS, GCxGC-HRMS)




Look for unknowns


- Chemistry driven approach
(look for particular signatures, e.g. halogens)



- Biology driven approach
(look for biological activity / toxicity, EDA)



- Statistic driven approach
(look for temporal trends, differential patterns)



What measuring?

Untargeted screening



Screening halogenated environmental contaminants in biota based on isotopic pattern and mass defect provided by high resolution mass spectrometry profiling

Ronan Cariou*, Elsa Omer, Alexis Léon, Gaud Dervilly-Pinel, Bruno Le Bizec

LUNAM UNIVERSITÉ, GMNRS, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LERICA), Nantes, F-44387, France

**analytical
chemistry**

Subscriber access provided by UNIV OF OREGON

Article


Automated detection of natural halogenated compounds from LC-MS profiles – Application to the isolation of bioactive chlorinated compounds from marine-derived fungi

Catherine Roulien, Yann GUITTON, Marine Valery, Séverine Amand, Soizic Prado, Thibaut Robiou du Pont, Olivier Grovel, and Yves François Pouchus


Anal. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.analchem.6b02128 • Publication Date (Web): 18 Aug 2016

Downloaded from http://pubs.acs.org on August 20, 2016

Sample prep. and HRMS strategies




Biocomputing data processing solutions



→ Already successful stories in environmental and food matrices.

Output: mass defect based maps of the detected features permitting to point out (and further identify) halogenated substances. Possible application to screen for not yet known novelt BFR, pesticides metabolites, Br/Cl phenols, BR+Cl POPs...

« HaloSeeker » user friendly application







Human Biomonitoring for EU
EJP Cofund H2020-SC1-2016-RTD,
733032, SC1-PM-05-2016

WP16

“Emerging chemicals”



Outline

- Introduction


- How measuring ?

- Where measuring ?

- When measuring ?


- What measuring ?

- Conclusion






How measuring?



- Sample preparation remains a corner stone
- Targeted quantitative methods still needed
- Untargeted profiling methods now the trend



When measuring?



- Need for longitudinal data and PBPK modeling
- Need for better experimental models
- MS profiling in personalized medicine




Where measuring?



- Need for more multi-compartment studies
- Stored vs. circulating ratio as integrative marker
- Non identical strategies for HBM / health studies



What measuring?



- Need for more extended characterizations...
- ... Following the exposome and mixture issues
- Need for integrating exposure / effect markers



- LABERCA's staff



laberca@oniris-nantes.fr
www.laberca.org
www.saraf-educ.org



- Financial supports



- Our Partners



Righospitalet, Copenhagen, DK

K Main, C Wohlfahrt Veje, NE Skakkebaeck

INSERM UMR-S 1124 & U755

R Barouki, X Coumoul, K Clément, MJ Kim

INRA UMR 1331 Toxalim (Mex & Axiom)

D Zalko, L Debrauwer

CHU de Toulouse

A Berrebi

INRA UMR 1331 PHAN

CY Boquien

CHU de Nantes

S Ploteau, A Legrand, C Bosher, JC Rozé

Oniris, AMAROC

J Abadie, F Morio, F Sauvaget



The HBM4EU WP16 consortium

L Debrauwer, A Covaci, R Vermeulen, J Vlanderen, M Krauss, H Oberacher, M Lamoree, AM Vinggaard, D Sarigiannis, J Klanova, Annelaure Damond, François Fenaille, JF Focant, T Santonen, M Horvat, G Sabbioni, M Nadal, JL Domingo, RM Balciene, R Barouki, M Kolossa.

MASS SPECTROMETRY FOR CHARACTERIZING HUMAN INTERNAL CHEMICAL EXPOSURE: STRENGTHS AND CHALLENGES



Laboratoire d'Étude des Résidus et Contaminants dans les Aliments (LABERCA)

USC INRA 1329, Oniris, LUNAM Université
BP 50707, 44307 Nantes Cedex 3, France - www.laberca.org



Jean-Philippe ANTIGNAC

Philippe Marchand, Ronan Cariou,
Bruno Veyrand, Anaïs Venisseau,
German Cano-Sancho, Stéphane Ploteau,
Emmanuelle Bichon, Ingrid Guiffard,
Yann Guitton, Fabrice Monteau, Bruno Le Bizec